Analyst firms · Morgan Stanley · BLUE
Morgan Stanley BLUE price target and rating history
bluebird bio Inc. (BLUE) · Health Care
Morgan Stanley rates bluebird bio Inc. (BLUE) Equal-Weight with a $7 price target, as of its latest action on Dec 8, 2023. It has published 5 rating actions on BLUE since July 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Equal-Weight
- Price target
- $7
- Median target, all firms
- Too few
- Actions on BLUE
- 5
Morgan Stanley price target on BLUE
Every Morgan Stanley rating on BLUE
- Dec 8, 2023
- Mar 7, 2022
- Jan 6, 2022
- Nov 8, 2021
- Jul 16, 2021
Questions about Morgan Stanley and BLUE
- What is Morgan Stanley's price target for BLUE?
- Morgan Stanley's latest stated price target for bluebird bio Inc. (BLUE) is $7, from its action on Dec 8, 2023.
- What is Morgan Stanley's rating on BLUE?
- Morgan Stanley rates BLUE Equal-Weight, a neutral rating, as of Dec 8, 2023.
- When did Morgan Stanley last change its view on BLUE?
- On Dec 8, 2023, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $3 to $7.
More BLUE rating histories
All Morgan Stanley ratingsBLUE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.